Eton Pharmaceuticals, Inc. (ETON) shares soared 6.7% in the last trading session to close at $23.81. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 24.5% gain over the past four weeks.Eton Pharmaceuticals’ stock price gain can be attributed to the latest FDA approval for Desmoda (desmopressin acetate) oral solution for the management of central diabetes insipidus (arginine vasopressin deficiency) across all age groups. In additi ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- ...

Eton Pharmaceuticals, Inc. (ETON) closed the last trading session at $20.77, gaining 14% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $31 indicates a 49.3% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $5.57. While the lowest estimate of $26.00 indicates a 25.2% increase from the current price level, the most optimistic ...

Eton posted GAAP net income of $1.5 million for the quarter, compared with a GAAP net loss of $0.6 million in the year-ago period. On a non-GAAP basis, net income was $5.4 million versus $0.7 million a year earlier. Adjusted EBITDA was $6.2 million, or 29% of revenue, up from $2.1 million, or 18%, in the prior-year quarter.Adjusted gross profit was $15.5 million, or 73% of revenue, compared with $6.8 million, or 59%, a year earlier. Gruber attributed the improvement to favorable product mix and manufacturin ...

分组1 - Eton Pharmaceuticals reported quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.12 per share, compared to a loss of $0.02 per share a year ago, representing an earnings surprise of -58.33% [1] - The company posted revenues of $21.28 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.22%, and this is an increase from year-ago revenues of $11.65 million [2] - Eton Pharmaceuticals has topped consensus revenue estimates four times over the last four quarters [2] 分组2 - The stock has added about 12.5% since the beginning of the year, while the S&P 500 has declined by 3.2% [3] - The current consensus EPS estimate for the coming quarter is $0.20 on $21.5 million in revenues, and for the current fiscal year, it is $1.02 on $103.84 million in revenues [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Eton Pharmaceuticals (NasdaqGM:ETON) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Company ParticipantsDavid Krempa - Chief Business OfficerIpek Erdogan-Trinkaus - Chief Commercial OfficerJames Gruber - CFOSean Brynjelsen - CEOConference Call ParticipantsChase Knickerbocker - Senior Equity Research Analyst of HealthcareMadison El-Saadi - Healthcare Research AnalystRamakanth Swayampakula - Managing Director and Senior Equity research AnalystOperatorGood afternoon, and welcome to the Eton Pharmaceuticals f ...

Eton Pharmaceuticals (NasdaqGM:ETON) Q4 2025 Earnings call March 19, 2026 04:30 PM ET Company ParticipantsDavid Krempa - Chief Business OfficerIpek Erdogan-Trinkaus - Chief Commercial OfficerJames Gruber - CFOSean Brynjelsen - CEOConference Call ParticipantsChase Knickerbocker - Senior Equity Research Analyst of HealthcareMadison El-Saadi - Healthcare Research AnalystRamakanth Swayampakula - Managing Director and Senior Equity research AnalystOperatorGood afternoon, and welcome to the Eton Pharmaceuticals f ...

Financial Data and Key Metrics Changes - Eton Pharmaceuticals reported fourth quarter product revenue of $21.3 million, an increase of 83% year-over-year, driven by strong performance from Alkindi Sprinkles and new products Increlex, Galzin, and KHINDIVI [5][38] - The adjusted EBITDA margin improved to 29%, up from 18% in the prior year period, indicating significant progress in profitability [6][45] - GAAP net income for the quarter was $1.5 million, compared to a net loss of $0.6 million in the prior year [46][47] Business Line Data and Key Metrics Changes - The launch of Increlex, Galzin, and KHINDIVI contributed significantly to revenue growth, with both Increlex and Galzin exceeding initial expectations [5][38] - Alkindi Sprinkles continued to perform strongly, contributing to the overall revenue increase [5][38] - The company expects adjusted gross margins to be comfortably above 70% for the full year, with potential to reach between 75% and 80% in the coming years [39][40] Market Data and Key Metrics Changes - The addressable market for DESMODA includes both pediatric and adult patients, expanding the potential patient base significantly beyond initial estimates [10][11] - The company anticipates a peak sales forecast of $30 million to $50 million for DESMODA, with initial demand showing strong traction [10][11] Company Strategy and Development Direction - Eton aims to build the largest rare disease portfolio in the U.S. and has set new long-term goals, including reaching a $200 million revenue run rate by the end of 2027 [32][33] - The company plans to optimize the distribution model for HEMANGEOL to improve operational efficiency and margin performance [20][21] - Eton is focused on maintaining profitability while pursuing growth, with a target of achieving a 50% adjusted EBITDA margin by 2028 [34][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for existing products and the successful integration of new acquisitions, including HEMANGEOL and DESMODA [31][60] - The company expects to generate significant operating cash flow throughout 2026 and beyond, indicating a positive outlook for financial health [48] Other Important Information - Eton's acquisition of HEMANGEOL was completed for $14 million in cash, avoiding dilution or incremental debt, which is expected to enhance earnings [24] - The company is preparing for a pilot initiative targeting adult endocrinologists for DESMODA, assessing the opportunity over the next 90 days [10] Q&A Session Summary Question: Growth assumptions for HEMANGEOL - Management believes that increasing patient adoption will be driven by a zero copay initiative and enhanced awareness efforts [50][51] Question: DESMODA's pace to peak sales - The launch of DESMODA has gone well, with expectations for quicker peak sales compared to previous products due to the specific unmet need it addresses [53][54] Question: Cash flow conversion from EBITDA in 2026 - The company anticipates being firmly in positive operating cash flow territory in 2026, with some timing considerations for supplier commitments [56][57] Question: $200 million run rate by end of 2027 - Management is confident that the existing product portfolio, including HEMANGEOL and DESMODA, will contribute significantly to achieving this goal [59][60]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 37-1858472 (I.R.S. Employer Identification No.) 21925 W. Field Parkway, Suite 235 Deer Park, IL 60010-7278 (Address of principal execu ...

Exhibit 99.1 Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results DEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2025. "It was another phenomenal quarter for Eton with meaningful contributions from key products across our portfolio in ...